Here is a summary of the latest #COVID19AB numbers: There are now 1,083 people in hospital due to COVID-19. Of the 836 non-ICU, 73.7% are unvaccinated or partially vaccinated. Of the 247 in ICU, 90.2% are unvaccinated or partially vaccinated. (1/5) pic.twitter.com/q5fL0Ijbjj
Today’s @clayandbuck talks an all time record yearly murder rate increase, the Afghan terrorist who killed 13 we let out of prison, LA enacts a covid vaccine mandate, FJB chants & big tech hearings. Listen & subscribe: podcasts.apple.com/us/podcast/the-clay-travis-and-buck-sexton-show/id1498106610?i=1000537767717
BREAKING—Los Angeles will require most people to provide proof of full coronavirus vaccination to enter a range of indoor businesses— restaurants, gyms, museums, movie theaters and salons. If rare exemption, then 72-hour negative #COVID19 test required. www.nytimes.com/2021/10/06/world/americas/los-angeles-vaccine-requirements.html
It’s because of you, the people of Ontario, that our province has one of the highest vaccination rates in the world. You have continued wearing masks, followed public health guidance, and rolled up your sleeves to get a COVID-19 vaccine. Thank you! pic.twitter.com/Q7rNqNp42x
06 October, 2021 - 12:06pm
There are two ways to think about the type of COVID-19 booster you can get: in one scenario, you get a homologous booster, which is the same shot you got for the initial series. A heterologous, or “mix-and-match” booster, lets you get a different vaccine based on availability or improved efficacy.
This is an important scientific distinction that will likely be used to further inform how COVID-19 booster shots will be rolled out in the U.S.
“There will be situations for one reason or another where a person may not have the availability to be boosted with the same product that they were originally vaccinated with,” Dr. Anthony Fauci, President Joe Biden’s chief medical adviser, told McClatchy last month.
But analysts say mixing COVID-19 shots could also dampen revenue projections for the vaccine market’s leaders.
“If ongoing mix-and-match trials show that the late entrants’ products are as effective at boosting as the original innovator vaccines themselves, then these companies stand to gain potentially meaningful near-term revenues and will almost certainly take significant share of whatever tail of future COVID vaccine revenue exists,” SVB Leerink analyst Geoffrey Porges told investors this week.
Roughly $19 billion of the sales generated so far over the past year came from selling the initial doses of their shots.
Those are considered homologous boosters.
But other research is under way assessing whether it’s okay to mix vaccines, and there are already some preliminary studies that indicate mixing vaccines is safe and could prompt a stronger immune response in some cases.
A U.S. study, which is being conducted by the National Institutes of Health and is testing a Moderna booster with other types of vaccines, is expected to make its findings public on Oct. 15 at a Food and Drug Administration advisory meeting assessing J&J’s booster application.
Results are also expected sometime this month from a U.K. trial called Cov-Boost.
A preprint published in June out of the U.K. found that mixing the BioNTech/Pfizer and AstraZeneca/University of Oxford vaccines triggered better immunity than using the AstraZeneca shots alone. Researchers in Germany said, also in June, that mixing the same vaccines as the U.K. could “improve immunogenicity and to mitigate potential intermittent supply shortages for individual vaccines.”
Depending on how the data shakes out, it could have a big impact on the market share held by the leading COVID-19 vaccine makers.
If clinical data shows that it’s safe and effective to use a different type of COVID-19 booster, that could allow some of the smaller companies developing still-investigational shots to gain entry and a slice of market share, according to Porges.
Leasing a ship can cost millions per month, making it an option only for the retailers with the biggest financial resources
Jaimy Lee is a health-care reporter for MarketWatch. She is based in New York.